Late-onset Pompe is routinely mistaken for limb-girdle muscular dystrophy. The patients are already in the system; they are under the wrong diagnosis.
Most Pompe patients have the late-onset form, and its presentation overlaps closely enough with limb-girdle muscular dystrophy that a substantial share sit misdiagnosed in neuromuscular clinics. The funnel therefore has to be built by phenotype rather than from headline prevalence, and case-finding in the misdiagnosed population is a larger source of volume than switching patients already on therapy.
Positioning a next-generation enzyme replacement therapy is a segment argument, not an average-patient argument. No challenger has cleanly beaten the long-established incumbent on its primary endpoint, and a value story that implies otherwise will not survive scrutiny. What differentiates is performance in a defined subgroup, and the case has to be built there and confined there.
Infusion burden and anti-drug antibodies belong in the value case as lifetime variables rather than per-cycle costs. Every approved therapy is a lifelong intravenous infusion, so the economics compound across decades: infusion-chair time, travel, immunogenicity management and the drug cost itself. Framed annually, next-generation agents look like a marginal upgrade at a premium; framed across a treatment lifetime, the argument changes.
AXLRx Pompe reports reconcile registry-confirmed counts against true prevalence across the US, UK and Gulf, size the switchable late-onset pool by phenotype, and build a lifetime-infusion value case rather than an annual one.
GAA-deficiency biology, the LOPD-versus-IOPD split, the years-long diagnostic delay, and newborn screening across the US Pompe population.
Pompe ERT costs near $400,000 a year in Part B, and remains the only major rare-disease ERT category ICER has never reviewed. Pombiliti + Opfolda splits into two simultaneous prior authorisations across Part B and Part D.
Two next-generation ERTs are moving to displace alglucosidase alfa in US late-onset Pompe disease. Avalglucosidase alfa and cipaglucosidase alfa plus miglustat now define the competitive set.
The UK Pompe Consortium registry counts roughly 200 confirmed patients. Total estimated prevalence, including the undiagnosed pool, runs 350-450. Within the confirmed, treated population, 30-50 are ADA-positive inadequate responders and 80-120 are on home ventilation.
Total GCC Pompe prevalence runs 400-600, consanguinity-elevated. 200-300 are actively managed on ERT, and NPHC's formulary budget centers on a narrower 80-120 long-term-stable core within that population.
Nexviazyme beat Lumizyme on 6-minute-walk distance in COMET, but NPHC has set no switch criteria. So 80-120 GCC ERT patients mostly stay on the 2006-era standard.
An ADA-positive-specific NICE case beats competing on incremental FVC improvement against alglucosidase. The 80-120 NIV-dependent LOPD patients are the highest-urgency target, and the BIMDG partnership shapes NICE's evidence bar.
A ~25% inadequate-ERT-responder subset defines the next-generation enzyme-replacement opportunity in UK Pompe. The UK Pompe Consortium's shared-care network sits against a 3–8 year late-onset diagnostic delay.
A new-entrant ERT cannot compete on NPHC-covered alglucosidase alone. The constraint is the NPHC step-edit plus Sanofi's entrenched home-infusion relationship at KFSH&RC, which any entrant must replicate from a standing start.
350-450 UK Pompe disease patients, of whom roughly 200 form the registry-confirmed cohort. One in four long-term ERT patients is not holding stable, the segment this model is built to size.
400-600 GCC Pompe disease patients, of whom 200-300 are on enzyme replacement therapy. Just 40-60, patients with FVC decline despite alglucosidase already on home ventilation, are the segment this model is built to size.
NHS England's Pompe commissioning policy defines a 45-50 patient switch-eligible cohort for avalglucosidase alfa (NICE TA821). That is a manageable NHS budget event; broader first-line uptake would be a materially larger one.
The ERT infusion access gap across GCC metabolic centres defines the Pompe opportunity. Newborn screening is expanding for infantile-onset disease, while late-onset still takes a limb-girdle diagnostic detour.
NPHC's well-established Pompe programme still gates avalglucosidase behind a 12-month failed-response switch criterion. Sanofi is pursuing NPHC first-line approval to bypass it.
Six to eight named metabolic centres across the GCC hold ERT infusion capacity for Pompe disease. KFSH&RC leads with roughly 120 patients over 15 years. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.
NICE accepts a £100,000-300,000 QALY threshold for ultra-rare Pompe disease, five to fifteen times the standard appraisal bar. That Highly Specialised Technologies ceiling is what avalglucosidase alfa's TA821 recommendation used, but only with a substantial confidential commercial arrangement. A new entrant without that leverage should build a standalone case for the antibody-positive inadequate-responder subgroup instead.
375–600 US LOPD patients are failing next-gen ERT — ADA superiority and first-line labeling decide who can reach them.
A six-physician BIMDG subcommittee advises NICE directly on Pompe disease. It sits at the centre of a five-centre UK Pompe Consortium and an eight-centre NHS Highly Specialised Service network. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.
US Pompe prevalence runs 5,000 to 10,000 patients, 70-80% late-onset. Of the roughly 2,000 LOPD patients on enzyme replacement therapy, 375 to 600 are inadequate responders, the addressable population any new agent must reach.
5,000-10,000 Americans live with Pompe disease. Roughly 2,000 late-onset patients are on enzyme replacement therapy, and 375-600 of them, one in four, are inadequate responders, the subtype this model is built to size.
Pompe ERT WAC runs near $400,000 a year, and the Pombiliti + Opfolda regimen splits across Medicare Part B and Part D. Zero ICER reviews exist today, with one expected in 2025 and a 12-month J-code lead time for any new entrant.
NHS-commissioned alglucosidase alfa runs £200,000-350,000 per patient a year post-PAS. Avalglucosidase alfa's NICE TA821 recommendation carries a 20-30% WAC premium and a switch-population budget impact of just £2-4M a year.
NPHC's annual Pompe ERT budget runs SAR 100-160M across 80-120 patients. That is SAR 800K-1.2M for alglucosidase versus SAR 1.2-1.8M for avalglucosidase. A new entrant should target SAR 2.0-2.5M a year, with switch approvals clearing at only 40-60%.
Avalglucosidase alfa's NICE recommendation (TA821) puts it against entrenched alglucosidase alfa. NHS switch criteria and the Pombiliti queue position define the next 18 months of UK access.
Pompe disease is a metabolic myopathy caused by acid alpha-glucosidase (GAA) deficiency. An estimated 5,000 to 10,000 people are affected in the US, of whom late-onset Pompe disease (LOPD) makes up 70 to 80 percent and infantile-onset disease (IOPD) the remainder. LOPD retains residual GAA activity above 1 percent and presents as proximal muscle weakness with progressive respiratory decline; IOPD shows near-absent GAA and hypertrophic cardiomyopathy within the first months of life. GCC consanguinity lifts incidence to 1:20,000 to 30,000 against roughly 1:40,000 globally.
Confirmation rests on a dried-blood-spot GAA enzyme assay, but the path there is slow. Late-onset patients are typically diagnosed years late, often after a limb-girdle muscular dystrophy workup, and in the GCC frequently not until forced vital capacity has fallen to 55 to 65 percent predicted. Newborn screening is reshaping the top of the funnel, Saudi Arabia added the GAA dried-blood-spot assay to its national panel in 2021 and expects 25 to 35 infantile-onset detections a year. The result is a wide gap between true prevalence and identified patients.
Three enzyme replacement therapies (ERTs) are FDA-approved. The incumbent, alglucosidase alfa (Lumizyme/Myozyme, Sanofi), dates to 2006 and 2010. Two next-generation agents now compete: avalglucosidase alfa (Nexviazyme, Sanofi, 2021), engineered for enhanced mannose-6-phosphate uptake, and cipaglucosidase alfa plus miglustat (Pombiliti plus Opfolda, Amicus Therapeutics, 2023), pairing an enzyme with an oral stabilising chaperone. All three are intravenous infusions, and the Amicus regimen adds co-administered oral Opfolda. In the COMET head-to-head, avalglucosidase was non-inferior to alglucosidase on forced vital capacity with a numerically greater 6-minute-walk gain.
The two phenotypes are found through separate mechanisms and must be sized separately. For infantile-onset disease we model the newborn-screening funnel, panel adoption by state or country, birth cohort, and confirmed detection rate, the pathway that led Saudi Arabia to project 25 to 35 detections a year after its 2021 GAA screening expansion. For late-onset disease we model a diagnosis funnel by phenotype: symptomatic prevalence, the share still mislabelled as limb-girdle muscular dystrophy, and conversion once a dried-blood-spot GAA assay is ordered. Each funnel yields a different identified count and a different growth curve, so a single prevalence number would misstate both the near-term addressable pool and its trajectory.
We build the funnel by phenotype rather than from headline prevalence. Starting from 5,000 to 10,000 US patients, roughly 70 to 80 percent are late-onset, of whom about 2,000 are on enzyme replacement therapy. Within that treated pool we size the inadequate-responder segment, an estimated 375 to 600 patients, or 25 to 30 percent, driven largely by the anti-drug antibodies that develop in 30 to 40 percent of treated patients. That switch-eligible cohort, not the prevalence figure, is the addressable market. Switch modelling then layers payer step-edits, which require documented inadequate response before a next-generation ERT is authorised, onto physician and centre-level switching intent.
Both are modelled as lifetime variables, not per-cycle costs. Every approved ERT is an intravenous infusion carrying roughly $400,000 a year in drug cost alone, so we build a lifetime-infusion value case that captures chair time, home-versus-hospital administration, and capacity constraints such as the 6 to 8 infusion centres serving the GCC. Anti-drug antibodies enter twice: as a clinical driver of the inadequate-responder segment, and as the sharpest switch rationale, since high-titre antibodies blunt response to first-generation enzyme. The value story therefore rests on immunogenicity-adjusted durability and administration burden, the levers a next-generation agent can move, rather than on a headline efficacy delta.
We position on the segment, not the average patient. Neither next-generation agent decisively beat alglucosidase on its primary endpoint, avalglucosidase reached non-inferiority with a numerically larger 6-minute-walk gain in COMET, while cipaglucosidase plus miglustat missed statistical superiority in PROPEL. Because no clean efficacy win exists, positioning turns on the antibody-positive inadequate responder and on switching economics rather than a first-line displacement claim. We test two strategic options against the evidence: an incremental-improvement claim across all treated patients, or a standalone submission built around the inadequate-responder subgroup, and we size each against the switch-eligible pool the funnel produces.
These questions sit on one thesis: in Pompe disease, the identification funnel is the strategy. AXLRx builds that funnel across the US, UK and GCC, reconciling registry-confirmed counts against true prevalence, separating the newborn-screening and late-onset diagnosis pathways, and sizing the inadequate-responder pool a new ERT can actually convert. Disease-landscape, market-sizing and patient-flow, competitive-intelligence, payer-and-pricing, and KOL-mapping work then turn that funnel into an access-gated commercial target. The output is not an epidemiology slide but an addressable, switch-eligible number a launch team can plan against.